LX
Lexeo Therapeutics, Inc. Common Stock
LXEO · NASDAQ
$3.39 -3.14% (-$0.11)
1M -32.34%
Market Cap $266.2M
P/E Ratio -
Div. Yield -
ROE 41.85%
Bulios Fair Price
$2.49
26.5% downside
Current Price
$3.39
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LXEO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.13x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 39.33%
ROE 41.85%
ROA 34.24%
Debt
69 /100
Low Debt/Equity 0.03x
Current ratio 13.89x
Int. coverage -631.36x
Stability
39 /100
Moderate Beta 1.50x
EPS volatility 32.65%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LXEO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
R. Nolan Townsend
Employees
63
Headquarters
New York City
Upcoming events
14 DEC
Earnings
Upcoming earnings report